Literature DB >> 7720767

CSF concentrations and clinical effects following intravenous dixyrazine premedication.

M Oikkonen1, J Kärkelä, T Seppälä.   

Abstract

Single concurrent plasma and lumbar spinal fluid samples were collected from twenty-two patients given IV dixyrazine 0.15 mg/kg, 10-106 min earlier in an open study. Dixyrazine penetrated rapidly into the spinal fluid; the CSF/P ratio was 0.3 by 10 min after drug administration and persisted at that level during the study period. The uncontrolled sedative and anxiolytic effects assessed by the patients were slight, and were correlated with the CSF drug concentrations only during the first 30 min after medication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720767     DOI: 10.1007/bf00196859

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Spinal descent of cerebrospinal fluid in man.

Authors:  G D Chiro; M K Hammock; W A Bleyer
Journal:  Neurology       Date:  1976-01       Impact factor: 9.910

2.  [Dixyrazin as premedication].

Authors:  A Bauer
Journal:  Lakartidningen       Date:  1974-01-30

3.  Premedication with intramuscular dixyrazine: (Esucos). A controlled double-blind comparison with morphine-scopolamine and placebo.

Authors:  S Larsson; M Hägerdal; D Lundberg
Journal:  Acta Anaesthesiol Scand       Date:  1988-02       Impact factor: 2.105

4.  The antiemetic effect of dixyrazine in postoperative patients-- a double-blind study.

Authors:  I Kivalo; P Rosenberg
Journal:  Ann Chir Gynaecol       Date:  1976

5.  Pharmacokinetics of dixyrazine: low bioavailability, improved by food intake.

Authors:  H Liedholm; A Lidén; L Kroon; A Melander; E Wåhlin-Boll
Journal:  Drug Nutr Interact       Date:  1985

6.  Temazepam versus flunitrazepam as an oral premedication in adult surgical patients.

Authors:  J Irjala; J Kanto; K Irjala; M Salonen; O Viinamäki
Journal:  Eur J Anaesthesiol       Date:  1987-11       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.